David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm for metastatic CRC at ASCO 2016
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content